Exor (ENXTAM:EXO) has quietly slipped over the past year, with shares down around 23% even as its underlying holdings like Ferrari and Stellantis keep executing. That gap is exactly what value focused ...
Philips resolved the Respironics litigation, settling for $1.1 billion. And Exor decided to boost its stake in the company. Supportive shareholders' remuneration is linked to Exor's portfolio results, ...
Exor announced the sale of a 4% stake in Ferrari to institutional investors, valued at €3 billion. This strategic move aims to diversify Exor's portfolio. Exor also plans a €1 billion buyback program ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback